Mirum Pharmaceuticals, Inc. 8-K

What Happened On January 12, 2026, Mirum Pharmaceuticals, Inc. (MIRM) issued a press release announcing preliminary unaudited net product sales for the fiscal year ended December 31, 2025 for its products LIVMARLI (maralixibat), CHOLBAM and CTEXLI, and disclosed preliminary unaudited cash, cash equivalents and investments. The company also posted a corporate slide presentation related to its participation in the J.P. Morgan Healthcare Conference on its Investor website. The press release and presentation were furnished as Exhibits 99.1 and 99.2 to the Form 8‑K.

Key Details

• Filing date: January 12, 2026.
• Announced preliminary unaudited net product sales for fiscal year ended December 31, 2025 for LIVMARLI, CHOLBAM and CTEXLI (specific amounts not included in this 8‑K).
• Reported preliminary unaudited cash, cash equivalents and investments (specific amounts not included in this 8‑K).
• Posted investor presentation for the J.P. Morgan Healthcare Conference on its website; the company stated it has no obligation to update the presentation.

Why It Matters The filing gives investors an early, company-reported view of 2025 product revenue trends and liquidity—key inputs for evaluating Mirum’s earnings performance and cash runway. Because the numbers are preliminary and unaudited, they are subject to revision when Mirum releases final audited results; the investor presentation may provide additional context on commercial performance and strategy ahead of formal financial disclosures.